Pitt's Coulter Program recently invested $575,000 in five innovative medical device technologies to advance them towards commercialization
The Coulter Program, Pitt’s on-campus biomedical accelerator housed in the Department of Bioengineering, recently invested over $575,000 in 5 innovative medical device technologies to advance them towards commercialization. This investment is in collaboration with Magee-Womens Research Institute, the School of Health and Rehabilitation Sciences, and the Department of Plastic Surgery.
2018 Funded projects:
In 2018, the Coulter Program also seed funded, Biodynamic Stereo-Radiography project in collaboration with the Innovation Institute and the Department of Orthopaedic Surgery.
Learn more about a few successful, Coulter-funded projects:
Koutif Therapeutics, which licensed patents from Pitt and the U.S. Department of Veterans Affairs, is pursuing a Phase I clinical trial of an investigational new drug targeted to diseases such as ulcerative colitis and Crohn's Disease. Coulter funded the E3: Novel FBXO3 anti-inflammatories technology which was a collaboration between Rama Mallampalli, MD and Bill Chen, PhD. Read more. >
Renerva, a Coulter funded, University of Pittsburgh spin-out company, received a $2.4 Million Department of Defense award to advance its peripheral nerve matrix technology to the clinic. Read more. >
AtlasMedTech, recently spun-out of the University under the leadership of CEO Joe Marcanio who incubated the company’s surgical tools technology as an Entrepreneur in Residence at the Innovation Institute with funding and support from the Coulter Program. Read more. >
Contact: Lindsay Rodzwicz